Alkermes (ALKS)
(Delayed Data from NSDQ)
$28.55 USD
+0.20 (0.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $28.56 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Company Summary
Dublin, Ireland-based Alkermes plc was formed by the Sep 2011 merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of Elan Corporation, plc. Elan was acquired by Perrigo in 2013. The combined entity is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products to address unmet medical needs of patients in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction ...
Company Summary
Dublin, Ireland-based Alkermes plc was formed by the Sep 2011 merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of Elan Corporation, plc. Elan was acquired by Perrigo in 2013. The combined entity is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products to address unmet medical needs of patients in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis.
Alkermes derives revenues on net sales of its proprietary products – Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia), and Lybalvi (schizophrenia and bipolar I disorder) and manufacturing and/or royalty revenues on net sales of products commercialized by the company’s partners. These include Ampyra/Fampyra (to improve walking in patients with multiple sclerosis) and Bydureon (type II diabetes). In October 2019, the FDA granted approval to Vumerity (diroximel fumarate), being developed in collaboration with Biogen to treat relapsing forms of multiple sclerosis (MS).
Further, Alkermes has a promising early-stage pipeline candidate, ALKS 2680, an investigational orexin 2 receptor agonist being developed for treating narcolepsy.
In November 2023, Alkermes completed the separation of its oncology business into an independent, publicly-traded company called Mural Oncology plc. The separation will allow Alkermes to focus on developing therapies for neurological conditions and improving profitability.
Vivitrol posted sales of $400.4 million in 2023, while Aristada generated sales worth $327.7 million in 2023. Lybalvi generated sales worth $191.9 million in 2023.
In 2023, Alkermes generated revenues of $1.66 billion, up 49.6% year over year.
General Information
Alkermes plc
1 BURLINGTON ROAD CONNAUGHT HOUSE
DUBLIN, L2 D04 C5Y6
Phone: 353-1772-8000
Fax: 781-890-0524
Email: investor_relations@alkermes.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/23/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.81 |
Current Year EPS Consensus Estimate | 2.75 |
Estimated Long-Term EPS Growth Rate | 20.30 |
Exp Earnings Date | 10/23/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 28.35 |
52 Week High | 32.88 |
52 Week Low | 20.49 |
Beta | 0.46 |
20 Day Moving Average | 1,551,148.62 |
Target Price Consensus | 34.69 |
4 Week | 2.15 |
12 Week | 18.47 |
YTD | 2.92 |
4 Week | 0.93 |
12 Week | 13.44 |
YTD | -13.91 |
Shares Outstanding (millions) | 164.67 |
Market Capitalization (millions) | 4,701.28 |
Short Ratio | NA |
Last Split Date | 5/15/2000 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 10.38 |
Trailing 12 Months | 12.52 |
PEG Ratio | 0.51 |
vs. Previous Year | 57.89% |
vs. Previous Quarter | 106.90% |
vs. Previous Year | -35.35% |
vs. Previous Quarter | 13.92% |
Price/Book | 3.66 |
Price/Cash Flow | 12.58 |
Price / Sales | 3.12 |
6/30/24 | 23.20 |
3/31/24 | 20.31 |
12/31/23 | 16.10 |
6/30/24 | 13.52 |
3/31/24 | 11.85 |
12/31/23 | 9.15 |
6/30/24 | 2.99 |
3/31/24 | 3.20 |
12/31/23 | 2.86 |
6/30/24 | 2.61 |
3/31/24 | 2.77 |
12/31/23 | 2.50 |
6/30/24 | 19.61 |
3/31/24 | 14.98 |
12/31/23 | 11.72 |
6/30/24 | 19.15 |
3/31/24 | 25.17 |
12/31/23 | 21.39 |
6/30/24 | 20.87 |
3/31/24 | 27.79 |
12/31/23 | 25.34 |
6/30/24 | 7.80 |
3/31/24 | 7.41 |
12/31/23 | 7.21 |
6/30/24 | 1.30 |
3/31/24 | 1.32 |
12/31/23 | 1.34 |
6/30/24 | 0.22 |
3/31/24 | 0.23 |
12/31/23 | 0.24 |
6/30/24 | 18.24 |
3/31/24 | 18.62 |
12/31/23 | 19.31 |